Detalhe da pesquisa
1.
Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.
Br J Cancer
; 130(6): 897-907, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38191608
2.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634928
3.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
4.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676282
5.
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 650-658, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35421369
6.
Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease.
Oncologist
; 26(12): 1026-1034, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355457
7.
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
Cancer
; 125(18): 3155-3163, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31150110
8.
The latest treatment options for bladder cancer.
Br Med Bull
; 128(1): 85-95, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30371744
9.
Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
J Urol
; 200(6): 1207-1214, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012366
10.
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
Cancer Cell Int
; 18: 71, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29760584
11.
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.
Acta Oncol
; 57(4): 491-497, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28853615
12.
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Invest New Drugs
; 35(5): 599-607, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28144789
13.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(11): 1599-1611, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720136
14.
Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).
Prostate
; 76(16): 1519-1527, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27457964
15.
Treatment of upper urinary tract urothelial carcinoma.
Lancet
; 395(10232): 1232-1234, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32145828
16.
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle-invasive bladder cancer.
Int J Cancer
; 136(3): 709-20, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24917520
17.
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Cancer
; 121(15): 2586-93, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25872978
18.
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
Ann Surg Oncol
; 22(4): 1377-84, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234022
19.
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 31(3): 760-8, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22907596
20.
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes.
Res Rep Urol
; 15: 321-331, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441525